PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Instinct Science, a leading innovator in veterinary workflow, decision support, education, and practice management software, has been named to the Inc. 5000 list of the fastest-growing private companies in America, earning the #388 spot overall, ranking #6 in Pennsylvania, and #37 in Software companies nationwide.
Key opportunities in the psychedelic drugs market include rising demand for mental health treatments, especially for conditions like depression and PTSD. Advances in clinical trials and regulatory support enhance acceptance, while integration with digital health tools augments care. Global policy reforms and decriminalization further bolster growth prospects.
Key opportunities in the psychedelic drugs market include rising demand for mental health treatments, especially for conditions like depression and PTSD. Advances in clinical trials and regulatory support enhance acceptance, while integration with digital health tools augments care. Global policy reforms and decriminalization further bolster growth prospects.
The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%. This growth is driven by increased healthcare needs, government initiatives to reduce pharmaceutical spending, and rising awareness of affordable alternatives. Supportive regulatory policies by the Saudi Food and Drug Authority (SFDA) and investments in local manufacturing are further spurring market expansion. The market is also bolstered by growing demand due to the rising prevalence of chronic diseases and increased acceptance among consumers and healthcare professionals.
The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%. This growth is driven by increased healthcare needs, government initiatives to reduce pharmaceutical spending, and rising awareness of affordable alternatives. Supportive regulatory policies by the Saudi Food and Drug Authority (SFDA) and investments in local manufacturing are further spurring market expansion. The market is also bolstered by growing demand due to the rising prevalence of chronic diseases and increased acceptance among consumers and healthcare professionals.
Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...
Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management functionPortfolio assets generate Total Income of $44.1...
MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm...
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...
NEW YORK and NEW ORLEANS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.